Surgical resection of locally advanced pulmonary adenocarcinoma after gefitinib therapy.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 21718818.
- Also identified by DOI 10.1016/j.athoracsur.2011.02.021.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
First-line therapy with gefitinib prolongs progression-free survival and improves quality of life among selected patients with non-small cell lung cancer. Selected locally advanced patients may derive benefit from surgical resection after gefitinib therapy. Further clinical trials are needed to evaluate the role of gefitinib therapy followed by surgical resection.
Medical subject headings
- Adenocarcinoma
- Lung Neoplasms
- Pneumonectomy
- Quinazolines